Adoptive transfer of lymphocytes transduced with MAGE-A4-specific TCR gene for therapy-resistant esophageal cancer
- Conditions
- Therapy-resistant esophageal cancer
- Registration Number
- JPRN-UMIN000002395
- Lead Sponsor
- Mie University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 9
Not provided
1.Having following serious complications # Uncontrolled anigina pectoris, myocardial infarction, or heart failure # Uncontrolled diabetes mellitus or hytertention # Uncontrolled infection # X-ray-proven interstitial pneumonia or pulmonary fibrosis # Autoimmune disease # Bleeding tendency; PT less than 50%, APTT more than 60sec, serum fibrinogen less than 100mg/dL, FDP more than 20ug/mL Thrombosis tendency 2.History of serious hypersensitivity 3.Positive for HBs Ag, HCV Ab, HIV Ab, or HTLV-I Ab 4. Unctrolled pleural effusion, ascites, or pericardial effusion 5.Uncontrolled CNS metastasis 6.Systemic corticostoroid or immuno-suppressive therapy 7. Inappropriate for MAGE-A4 143-151 peptide administration, i.e. allergic to the peptide or adjuvant 8.Mental illness or drug dependency affecting informed consent 9.Pregnant, lactating, or possiblly pregnant women, or willing to be pregnant, or willing male partner, except having cryopreseved sperm 10. Lasting less than four weeks from the previous enrollment to clinical trials 11.Inappropriate for study entry judged by an attending physician.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method